Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Biotech Is Getting A Big Boost Following Clinton's Loss

LLY, XBI, IBB, MRK, AMGN, GILD, PFE, NVS

Investors in biotech stocks were getting a little weary leading up to the Presidential elections. However, with the results in favor of Donald Trump, biotech stocks are trading higher.

Some of the stocks are gaining significantly in Wednesday's pre-market session. Clinton was not happy with drug pricing by pharmaceutical firms, and many feared of the price cuts and regulations her presidency might bring to the table.

The following stocks gained in the pre-market trading on Wednesday:

  • SPDR S&P Biotech (ETF) (NYSE: XBI) trading up 4.8 percent to $60.60
  • iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) added 4.33 percent to $272.96.
  • Valeant Pharmaceuticals Intl Inc (NYSE: VRX), which tanked 21.69 percent on Tuesday, gained 1.13 percent to $15.15.
  • Mylan NV (NASDAQ: MYL) jumped 5.85 percent to $39.28.
  • Pfizer Inc. (NYSE: PFE) advanced 7.33 percent to $32.25.
  • Eli Lilly and Co (NYSE: LLY) gained 3.01 percent to $76.25.
  • Amgen, Inc. (NASDAQ: AMGN) was up 2.82 percent to $142.35.
  • Gilead Sciences, Inc. (NASDAQ: GILD) added 1.94 percent to $75.50.
  • Merck & Co., Inc. (NYSE: MRK) gained 2.88 percent to $62.25.
  • Novartis AG (ADR) (NYSE: NVS) advanced 2.41 percent to $73.00.


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today